BioPharmSignal logoBioPharmSignal

Biotech News

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Intellia (NTLA)IntelliaCompany update

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that management will be participating in fireside chats

Open original release

Related news

NTLAIntellia2026-06-13 11:30 EST

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

NTLAIntellia2026-06-01 11:30 EST

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

SRPTSarepta Therapeutics2026-06-01 20:30 EST

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

CRSPCRISPR Therapeutics2026-05-28 12:00 EST

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ABEOAbeona Therapeutics2026-05-26 12:30 EST

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

EDITEditas Medicine2026-02-23 14:00 EST

Editas Medicine to Participate in Upcoming Investor Conferences

RCKTRocket Pharmaceuticals2026-02-23 12:00 EST

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

PASGPassage Bio2026-02-19 12:00 EST

Passage Bio to Participate in Upcoming Investor Conferences

CRBUCaribou2026-02-12 21:05 EST

Caribou Biosciences to Participate in Upcoming Investor Conferences

SANASana Biotechnology2026-05-27 20:05 EST

Sana Biotechnology to Present at June 2026 Investor Conferences

View all latest news

Intellia

Intellia Therapeutics is a gene-editing company building in vivo and ex vivo CRISPR programs across serious genetic diseases.

Recent company news

NTLAIntellia2026-07-06 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-06-13 11:30 EST

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

NTLAIntellia2026-06-05 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-06-01 11:30 EST

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

NTLAIntellia2026-05-11 11:30 EST

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Stock data

Close
10.67 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States